120 related articles for article (PubMed ID: 12559562)
1. The ETO (MTG8) gene family.
Davis JN; McGhee L; Meyers S
Gene; 2003 Jan; 303():1-10. PubMed ID: 12559562
[TBL] [Abstract][Full Text] [Related]
2. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
[TBL] [Abstract][Full Text] [Related]
3. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
Lutterbach B; Sun D; Schuetz J; Hiebert SW
Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
[TBL] [Abstract][Full Text] [Related]
4. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21).
Nucifora G; Rowley JD
Leuk Lymphoma; 1994 Aug; 14(5-6):353-62. PubMed ID: 7812194
[TBL] [Abstract][Full Text] [Related]
5. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.
Lam K; Zhang DE
Front Biosci (Landmark Ed); 2012 Jan; 17(3):1120-39. PubMed ID: 22201794
[TBL] [Abstract][Full Text] [Related]
7. ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator of early adipogenesis.
Rochford JJ; Semple RK; Laudes M; Boyle KB; Christodoulides C; Mulligan C; Lelliott CJ; Schinner S; Hadaschik D; Mahadevan M; Sethi JK; Vidal-Puig A; O'Rahilly S
Mol Cell Biol; 2004 Nov; 24(22):9863-72. PubMed ID: 15509789
[TBL] [Abstract][Full Text] [Related]
8. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.
Hatlen MA; Wang L; Nimer SD
Front Med; 2012 Sep; 6(3):248-62. PubMed ID: 22875638
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
10. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
12. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1.
Kitabayashi I; Ida K; Morohoshi F; Yokoyama A; Mitsuhashi N; Shimizu K; Nomura N; Hayashi Y; Ohki M
Mol Cell Biol; 1998 Feb; 18(2):846-58. PubMed ID: 9447981
[TBL] [Abstract][Full Text] [Related]
13. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia.
Rowley JD
Ann Genet; 1973 Jun; 16(2):109-12. PubMed ID: 4125056
[No Abstract] [Full Text] [Related]
14. RUNX1-ETO Leukemia.
Lin S; Mulloy JC; Goyama S
Adv Exp Med Biol; 2017; 962():151-173. PubMed ID: 28299657
[TBL] [Abstract][Full Text] [Related]
15. Structure and expression of the human MTG8/ETO gene.
Wolford JK; Prochazka M
Gene; 1998 May; 212(1):103-9. PubMed ID: 9661669
[TBL] [Abstract][Full Text] [Related]
16. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
17. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
18. CPEB3 Maintains Developmental Competence of the Oocyte.
Lamacova L; Jansova D; Jiang Z; Dvoran M; Aleshkina D; Iyyappan R; Jindrova A; Fan HY; Jiao Y; Susor A
Cells; 2024 May; 13(10):. PubMed ID: 38786074
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma.
Rock A; Uche A; Yoon J; Agulnik M; Chow W; Millis S
J Pers Med; 2023 Oct; 13(10):. PubMed ID: 37888109
[TBL] [Abstract][Full Text] [Related]
20. The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.
Kugler E; Madiwale S; Yong D; Thoms JAI; Birger Y; Sykes DB; Schmoellerl J; Drakul A; Priebe V; Yassin M; Aqaqe N; Rein A; Fishman H; Geron I; Chen CW; Raught B; Liu Q; Ogana H; Liedke E; Bourquin JP; Zuber J; Milyavsky M; Pimanda J; Privé GG; Izraeli S
Nat Commun; 2023 Sep; 14(1):5871. PubMed ID: 37735473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
